Sugi Predict

Sugi Predict / Compounds / SCHEMBL125503

SCHEMBL125503

SCHEMBL125503

CC(C)(C)OC(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.52
▸ MAOA P21397 1/20 0.49
▸ MAOB P27338 1/20 0.49
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ GAA P10253 1/20 0.48
▸ CA2 P00918 4/20 0.47
▸ CA12 O43570 3/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ CYP2D6 P10635 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ CA1 P00915 3/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ EPHX1 P07099 1/20 0.42
▸ EPHX2 P34913 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23332545 0.92 TDP1 (0.46) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL3187413 0.88 TDP1 (0.50) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL523837 0.88 CA2 (0.59) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL15228711 0.87 TDP1 (0.46) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL4714065 0.86 TDP1 (0.52) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL18295819 0.86 TDP1 (0.44) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL16270955 0.85 MAOA (0.49) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL7530750 0.84 MAOA (0.57) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL959018 0.84 TDP1 (0.50) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL10004845 0.84 TDP1 (0.50) TDP1MAOAMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112194598-A Process for the preparation of 3- (tert-butoxycarbonyl-ethoxycarbonylmethyl-amino) -propanoate 郑州猫眼农业科技有限公司 2021-01-08 — — CN claimed
CN-106905444-B Icariin and the conjugate of hyaluronic acid and its preparation method and application 张君涛 2019-07-23 — — CN claimed
CN-108623647-A Chinese medicine with Detectable effects 天津中医药大学第附属医院 2018-10-09 — — CN claimed
CN-106905444-A Conjugate of icariin and hyaluronic acid and its preparation method and application 张君涛 2017-06-30 — — CN claimed
EP-0903382-A1 Semi-solid hot melt ink compositions containing esters XEROX CORPORATION (US) 1999-03-24 — — EP claimed
US-5876492-A Ink compositions containing esters XEROX CORPORATION (US) 1999-03-02 — — US claimed
CN-119745915-A Preparation method of hydrogel conjugate for treating arthritis 湖南中医药大学第一附属医院((中医临床研究所)) 2025-04-04 — — CN disclosed
WO-2024235254-A1 BIARYL COMPOUNDS PREPARATION METHODS AND MEDICINAL USES THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-11-21 — — WO disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
US-20240228451-A1 METHODS OF SYNTHESIZING LIPSTATIN DERIVATIVES PANAFINA, INC. 2024-07-11 — — US disclosed
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE NOVARTIS AG (CH) 2024-07-04 — — US disclosed
CN-118256591-A Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-06-28 — — CN disclosed
CN-118184532-A Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same 中外制药株式会社 2024-06-14 — — CN disclosed
US-20050222189-A1 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors VERNALIS (OXFORD) LTD (GB) 2005-10-06 — — US disclosed
US-20030207865-A1 Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents DIXON BRIAN R (US) 2003-11-06 — — US disclosed
US-6353006-B1 TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT BAYER CORPORATION 2002-03-05 — — US disclosed
EP-1144396-A2 SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS Bayer Corporation (US) 2001-10-17 — — EP disclosed
WO-2000042031-A2 SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS BAYER CORPORATION (US) 2000-07-20 — — WO disclosed
EP-0903382-A1 Semi-solid hot melt ink compositions containing esters XEROX CORPORATION (US) 1999-03-24 — — EP disclosed
US-5876492-A Ink compositions containing esters XEROX CORPORATION (US) 1999-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228451-A1 METHODS OF SYNTHESIZING LIPSTATIN DERIVATIVES PNLIP, LIPC, LIPE TDP1 614/4885MAOA 609/4885MAOB 135/4885
US-20050222189-A1 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors MMP9, TIMP3, MMP13 TDP1 1360/4885MAOA 126/4885MAOB 84/4885
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE FASN, FABP1, SCD TDP1 2945/4885MAOA 405/4885MAOB 769/4885
US-20030207865-A1 Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents PGR, PGRMC2, PGRMC1 TDP1 3939/4885MAOA 1298/4885MAOB 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.